Cubicin Correction Certificate Dooms Patent, Fed. Circ. Told
Hospira Inc. on Tuesday urged the Federal Circuit to reverse a decision upholding the validity of a patent for blockbuster infection drug Cubicin, saying the lower court should have invalidated Cubist...To view the full article, register now.
Already a subscriber? Click here to view full article